HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SUPN

Supernus Pharmaceuticals Inc

Last Close
Mar 21 • 04:00PM ET
32.15
Dollar change
-0.17
Percentage change
-0.53 		%
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD
Peers: NBIX ACAD TEVA UTHR INSM AXNX PTCT DRRX MNKD XENE
 | Held by: IJR VTI IWM VB AVUV VBR VXF SPSM IWN CALF
Scroll to Statements
IndexRUT P/E24.39 EPS (ttm)1.32 Insider Own4.43% Shs Outstand55.74M Perf Week2.85%
Market Cap1.79B Forward P/E12.66 EPS next Y2.54 Insider Trans-12.23% Shs Float53.34M Perf Month-7.05%
Income73.86M PEG36.95 EPS next Q0.36 Inst Own108.76% Short Float11.36% Perf Quarter-11.24%
Sales661.82M P/S2.71 EPS this Y-37.53% Inst Trans-1.28% Short Ratio11.42 Perf Half Y0.97%
Book/sh18.58 P/B1.73 EPS next Y29.37% ROA5.08% Short Interest6.06M Perf Year-8.53%
Cash/sh8.13 P/C3.96 EPS next 5Y0.66% ROE7.55% 52W Range25.53 - 40.28 Perf YTD-11.09%
Dividend Est.- P/FCF10.48 EPS past 5Y-8.87% ROI6.95% 52W High-20.18% Beta0.92
Dividend TTM- Quick Ratio2.16 Sales past 5Y11.80% Gross Margin76.08% 52W Low25.93% ATR (14)1.15
Dividend Ex-Date- Current Ratio2.35 EPS Y/Y TTM5171.26% Oper. Margin11.08% RSI (14)41.66 Volatility2.75% 3.84%
Employees674 Debt/Eq0.03 Sales Y/Y TTM8.94% Profit Margin11.16% Recom2.20 Target Price38.80
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q1174.65% Payout0.00% Rel Volume4.24 Prev Close32.32
Sales Surprise12.18% EPS Surprise43.54% Sales Q/Q5.99% EarningsFeb 25 AMC Avg Volume530.79K Price32.15
SMA200.45% SMA50-9.83% SMA200-3.49% Trades Volume2,250,290 Change-0.53%
Date Action Analyst Rating Change Price Target Change
Feb-19-25Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $36
Jan-06-25Initiated Cantor Fitzgerald Overweight $57
Sep-11-24Downgrade Piper Sandler Overweight → Neutral $41 → $36
Jan-03-23Resumed Jefferies Buy $44 → $45
Dec-01-21Resumed Jefferies Buy $40 → $44
Apr-13-21Upgrade Jefferies Hold → Buy $25 → $40
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Show Previous Ratings
Mar-17-25 09:35AM
Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround
(Zacks)
Mar-14-25 05:01AM
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
(StockStory)
Mar-13-25 09:00AM
3 Small-Cap Stocks Skating on Thin Ice
(StockStory)
Mar-06-25 07:24PM
Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts
(Insider Monkey)
Mar-04-25 04:30PM
Supernus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
04:06AM Loading…
04:06AM
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
(StockStory)
04:03AM
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
(StockStory)
Mar-02-25 12:16PM
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?
(Insider Monkey)
Feb-27-25 08:30AM
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
(GlobeNewswire)
Feb-26-25 12:51PM
Q4 2024 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
02:14AM
Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
(GuruFocus.com)
Feb-25-25 06:30PM
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
(Zacks)
05:45PM
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
(Zacks)
05:28PM
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
(StockStory)
04:53PM
Supernus: Q4 Earnings Snapshot
(Associated Press Finance)
04:01PM Loading…
04:01PM
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Feb-24-25 08:06AM
What To Expect From Supernus Pharmaceuticalss (SUPN) Q4 Earnings
(StockStory)
Feb-19-25 10:29AM
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
(Benzinga) -15.67%
Feb-18-25 04:25PM
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
(GlobeNewswire)
Feb-11-25 04:30PM
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Feb-06-25 12:00PM
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
(Zacks)
07:48AM
Supernus wins FDA approval for Parkinsons pump on fourth try
(Pharmaceutical Technology)
Feb-04-25 09:00AM
Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's Disease
(GlobeNewswire) +7.07%
Jan-30-25 06:22AM
7MM PD market to grow by $4.5bn between 2023 and 2033
(Clinical Trials Arena)
Jan-27-25 08:00AM
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree , Including New Pharmacodynamic Data and Information for Breastfeeding Women
(GlobeNewswire)
Dec-16-24 04:30PM
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree (viloxazine) in Canada
(GlobeNewswire)
Nov-26-24 05:00PM
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-13-24 04:30PM
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
(GlobeNewswire)
Nov-05-24 08:00AM
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
Nov-04-24 08:00PM
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
(Zacks)
07:35PM Loading…
07:35PM
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
(Zacks)
06:33PM
Supernus: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
Supernus Announces Third Quarter 2024 Financial Results
(GlobeNewswire)
Oct-31-24 04:10PM
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
(GlobeNewswire)
Oct-21-24 04:25PM
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
(GlobeNewswire)
Oct-18-24 08:31PM
Supernus depression drug improved symptoms in two hours in Phase IIa study
(Clinical Trials Arena)
Oct-17-24 04:05PM
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
(GlobeNewswire)
Oct-10-24 05:12PM
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
(GlobeNewswire)
Oct-09-24 05:07PM
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
Sep-24-24 07:30AM
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
(GlobeNewswire)
Sep-19-24 04:30PM
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
(GlobeNewswire)
Sep-16-24 10:50AM
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
(Insider Monkey)
Sep-11-24 02:38PM
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
(Benzinga) -7.20%
Aug-28-24 04:15PM
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
(GlobeNewswire)
Aug-19-24 07:00AM
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
(GlobeNewswire)
Aug-09-24 09:55AM
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
(Zacks)
Aug-06-24 08:00PM
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
(Zacks) +14.49%
06:45PM
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
(Zacks)
05:36PM
Supernus: Q2 Earnings Snapshot
(Associated Press Finance)
04:06PM
Supernus Announces Second Quarter 2024 Financial Results
(GlobeNewswire)
Aug-01-24 04:30PM
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
(GlobeNewswire)
Jul-23-24 04:13PM
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
(GlobeNewswire)
Jul-19-24 01:58PM
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
(InvestorPlace)
May-30-24 04:25PM
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-24-24 11:53AM
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
(Zacks)
May-23-24 04:05PM
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
(GlobeNewswire)
May-10-24 01:38PM
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
(GuruFocus.com)
May-09-24 04:05PM
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
(GlobeNewswire)
11:56AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
(Insider Monkey)
03:42AM
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 10:56PM
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
(InvestorPlace)
07:00PM
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
(Zacks)
04:05PM
Supernus Announces First Quarter 2024 Financial Results
(GlobeNewswire)
May-07-24 11:46AM
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
(MT Newswires)
10:00AM
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree (Viloxazine XR) in Latin America
(PR Newswire)
09:15AM
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
(Zacks)
May-01-24 08:00AM
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
(GlobeNewswire)
Apr-24-24 04:05PM
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
(GlobeNewswire)
Apr-08-24 12:11PM
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
(Benzinga) -6.32%
08:00AM
Supernus Provides Regulatory Update for SPN-830
(GlobeNewswire)
Mar-27-24 04:37PM
Corporate Insiders Are Selling These 10 Small-Cap Stocks
(Insider Monkey)
Mar-06-24 04:30PM
Supernus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Mar-04-24 08:28PM
11 Best Small Cap Pharma Stocks to Invest In
(Insider Monkey)
Feb-28-24 04:30PM
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
(GlobeNewswire)
09:19AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
(Insider Monkey)
07:17AM
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
Feb-27-24 07:30PM
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
(Zacks)
06:50PM
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
(Zacks)
06:02PM
Supernus: Q4 Earnings Snapshot
(Associated Press Finance)
05:00PM
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
(GuruFocus.com)
04:05PM
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Feb-26-24 09:15AM
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
(Zacks)
Feb-20-24 10:00AM
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Feb-13-24 04:05PM
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
(GlobeNewswire)
Feb-05-24 08:30AM
Supernus Wins Infringement and Validity Case on Trokendi XR against Torrent
(GlobeNewswire)
Dec-19-23 07:30AM
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada
(GlobeNewswire)
Dec-14-23 07:43PM
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
(InvestorPlace)
Nov-18-23 05:03AM
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...
(GuruFocus.com)
Nov-10-23 12:10PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-09-23 09:54AM
Q3 2023 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents) +11.14%
Nov-08-23 07:30PM
Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
(Zacks)
07:15PM
Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
06:08PM
Supernus: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
Supernus Announces Third Quarter 2023 Financial Results
(GlobeNewswire)
Nov-07-23 04:30PM
Supernus to Participate in the Jefferies London Healthcare Conference
(GlobeNewswire)
Nov-02-23 07:00AM
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
(GlobeNewswire)
Nov-01-23 10:01AM
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
(Zacks)
Oct-25-23 04:15PM
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
(GlobeNewswire)
Oct-16-23 05:34PM
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
(GlobeNewswire)
Oct-09-23 04:45PM
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
(GlobeNewswire)
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Khattar Jack A.President, CEOMar 10 '25Option Exercise0.0035,00001,008,638Mar 11 04:17 PM
DEC TIMOTHY CSenior Vice-President & CFOMar 10 '25Option Exercise0.003,800013,636Mar 11 04:15 PM
Khattar Jack A.President, CEOMar 07 '25Option Exercise0.0038,6400992,219Mar 07 04:40 PM
Mottola FrankSVP, Quality, GMP, Ops, ITMar 07 '25Option Exercise0.002,625016,507Mar 07 04:34 PM
Mottola FrankSVP, Quality, GMP, Ops, ITFeb 26 '25Option Exercise0.005,760017,683Feb 26 05:56 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 21 '25Option Exercise0.001,650011,799Feb 24 08:22 PM
Rubin JonathanSVP, Chief Medical OfficerFeb 21 '25Option Exercise0.001,87508,780Feb 24 08:20 PM
Rubin JonathanSVP, Chief Medical OfficerFeb 21 '25Sale39.1592736,2927,853Feb 24 08:20 PM
Mottola FrankSVP, Quality, GMP, Ops, ITFeb 21 '25Option Exercise0.001,12509,576Feb 24 08:18 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 04 '25Option Exercise29.619,477280,61419,626Feb 05 04:37 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 04 '25Sale39.709,477376,23710,149Feb 05 04:37 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 27 '25Option Exercise29.612,57376,18712,722Jan 29 05:04 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 28 '25Option Exercise29.6170020,72710,849Jan 29 05:04 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 27 '25Sale39.622,573101,94210,149Jan 29 05:04 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 28 '25Sale39.6270027,73410,149Jan 29 05:04 PM
PADMANABH BHATTOfficerJan 27 '25Proposed Sale38.5522,000848,100Jan 27 04:26 PM
Hudson Frederick M.DirectorJan 22 '25Option Exercise9.1320,000182,60048,395Jan 23 04:33 PM
Rubin JonathanSVP, Chief Medical OfficerDec 27 '24Option Exercise0.002,62507,416Dec 30 04:13 PM
Khattar Jack A.President, CEODec 27 '24Option Exercise0.0052,6400964,812Dec 30 04:08 PM
Bhatt Padmanabh P.Sr. VP of IP, CSODec 03 '24Option Exercise24.7721,495532,36122,424Dec 04 04:36 PM
Bhatt Padmanabh P.Sr. VP of IP, CSODec 03 '24Sale36.6821,495788,4379,679Dec 04 04:36 PM
PADMANABH P BHATTOfficerDec 03 '24Proposed Sale37.3121,495801,978Dec 03 04:31 PM
NEWHALL CHARLES W IIIDirectorNov 11 '24Option Exercise9.1320,000182,600140,975Nov 12 04:15 PM
NEWHALL CHARLES W IIIDirectorNov 11 '24Sale36.2410,700387,768130,275Nov 12 04:15 PM
Hudson Frederick M.DirectorNov 08 '24Sale36.288,722316,43428,395Nov 12 04:14 PM
GEMAYEL GEORGESDirectorNov 08 '24Option Exercise11.4610,787123,61924,102Nov 12 04:13 PM
GEMAYEL GEORGESDirectorNov 08 '24Sale36.3010,787391,56813,315Nov 12 04:13 PM
Khattar Jack A.President, CEONov 08 '24Option Exercise9.13125,0001,141,2501,051,172Nov 12 04:11 PM
Khattar Jack A.President, CEONov 08 '24Sale36.29125,0004,536,250926,172Nov 12 04:11 PM
CHARLES NEWHALLOfficerNov 11 '24Proposed Sale36.2410,700387,775Nov 12 09:18 AM
JACK A KHATTAROfficerNov 08 '24Proposed Sale36.29125,0004,535,850Nov 08 05:00 PM
FREDERICK M HUDSONDirectorNov 08 '24Proposed Sale36.288,722316,476Nov 08 04:33 PM
GEORGES GEMAYELDirectorNov 08 '24Proposed Sale36.3010,787391,536Nov 08 04:19 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 07 '24Option Exercise9.1315,000136,95023,200Nov 08 04:13 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 07 '24Sale36.9815,000554,7008,200Nov 08 04:13 PM
GEMAYEL GEORGESDirectorNov 07 '24Option Exercise11.4614,213162,88127,528Nov 08 04:11 PM
GEMAYEL GEORGESDirectorNov 07 '24Sale36.6214,213520,48013,315Nov 08 04:11 PM
Khattar Jack A.President, CEONov 07 '24Option Exercise9.13125,0001,141,2501,051,172Nov 08 04:08 PM
Khattar Jack A.President, CEONov 07 '24Sale36.68125,0004,585,000926,172Nov 08 04:08 PM
JACK A KHATTAROfficerNov 07 '24Proposed Sale36.68125,0004,584,600Nov 07 04:59 PM
FRANK MOTTOLAOfficerNov 07 '24Proposed Sale36.9815,000554,692Nov 07 04:55 PM
GEORGES GEMAYELDirectorNov 07 '24Proposed Sale36.6214,213520,511Nov 07 04:42 PM
GEMAYEL GEORGESDirectorSep 13 '24Option Exercise11.4610,000114,60023,315Sep 17 04:10 PM
GEMAYEL GEORGESDirectorSep 13 '24Sale31.3313,886435,04813,315Sep 17 04:10 PM
GEORGES GEMAYELDirectorSep 13 '24Proposed Sale31.3313,886435,041Sep 13 04:30 PM
Khattar Jack A.President, CEOSep 03 '24Option Exercise0.0021,0000936,217Sep 03 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOAug 20 '24Option Exercise0.001,250010,251Aug 20 05:00 PM
TAMI TILLOTSON MARTINFormer OfficerAug 02 '24Proposed Sale29.024,000116,074Aug 02 04:16 PM
TAMI TILLOTSON MARTINFormer OfficerAug 01 '24Proposed Sale29.313,10090,856Aug 01 04:19 PM
TAMI TILLOTSON MARTINFormer OfficerJul 31 '24Proposed Sale30.135,000150,650Jul 31 04:41 PM
TAMI TILLOTSON MARTINFormer OfficerJul 30 '24Proposed Sale30.562,90088,610Jul 30 04:02 PM
TAMI TILLOTSON MARTINFormer OfficerJul 29 '24Proposed Sale30.755,000153,750Jul 29 04:08 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.